• Publications
  • Influence
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
TLDR
Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
TLDR
NeoTx for resectable pancreatic cancer was associated with a median overall survival of 32 months; something not reported for patients treated with surgery first if based on intent-to-treat analysis.
Predictive and Prognostic Markers in Colorectal Cancer
TLDR
This article focuses on prognostic and predictive markers in CRC that have a substantial body of data in support of their potential role in routine clinical practice.
Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy
TLDR
Borderline resectable disease was used to define those patients with arterial abutment and short segment venous (superior mesenteric–portal vein [SMVPV]) occlusion who, in the past, would have been considered locally advanced and may be at higher risk for harboring radiographically occult distant metastatic disease.
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
TLDR
In targeted genomic profile analyses of 3594 PDACs, 17% were found to contain genomic alterations that might make the tumor cells susceptible to currently used anticancer agents and these alterations might be used as biomarkers for early detection.
Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma
TLDR
The use of chemotherapy was associated with a survival benefit only for ICC patients with nodal metastasis, advanced tumor stage, or an inadequate surgical resection, and Chemotherapy for resected ICC should be strongly considered for tumors harboring high-risk features.
Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease.
TLDR
In the evolving landscape of multimodality therapy, selective hepatic resection for CRLM patients with EHD is feasible with potential impact on survival and patients with minimal liver disease and EHD in the lung achieve the best outcome.
High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.
TLDR
In comparison to SCLC, less than half of the patients with colorectal HGNEC have history of smoking; metastatic patterns are also different between the 2 cancers; and a multimodality approach seems to be associated with better outcomes, while systemic chemotherapy is the mainstay of treatment for advanced disease.
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
TLDR
The genomics and immune features associated with hyperprogressive disease may help identify patients at risk of adverse clinical outcome after anti-PD-1 immunotherapy, and a gene expression signature predictive of HPD is developed.
...
1
2
3
4
5
...